Syndromic Multiplex Diagnostic Market is Likely to Upsurge CAGR of 8.7% by 2029

The Latest released Global Syndromic Multiplex Diagnostic Market Research Report provides a detailed assessment of Key and emerging players showcasing company profiles, product/service offerings, market price, and sales revenue to better derive market size estimation. The most appropriate, exclusive, realistic, and admirable Global Syndromic Multiplex Diagnostic Market Research report is delivered with loyalty to all business needs.

Syndromic multiplex diagnostic is a type of advanced diagnostic test utilized to detect infectious diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. The syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.

Data Bridge Market Research analyses that the global syndromic multiplex diagnostic market will grow at a CAGR of 8.7% during the forecast period of 2022 to 2029.

Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-syndromic-multiplex-diagnostic-market

Market Overview:

Syndromic multiplex testing is used to diagnose many pathogens simultaneously. In the syndromic multiplex diagnostic, various types of reagents & consumables and instruments & accessories are used, which helps maintain accuracy and provide fast diagnosis results. These multiplex tests are rapidly diagnosed with certain infections, allowing clinical management decisions to be made promptly. The tests based on multiplex technology are known as test panels. The panels used in syndromic testing are designed to diagnose multiple diseases associated with the same or similar syndrome type. These panels help evaluate the cause of the disease at the point of care. Gastrointestinal panels and respiratory panels are the types of syndromic panels.

Syndromic multiplex testing utilizes the advanced technology of multiplex PCR which provides accurate and fast diagnostic results with the help of the multiple panels used in syndromic multiplex diagnostic to provide diagnostic results within an hour. The new generations of syndromic multiplex can rapidly identify the common type of pathogens in the respiratory specimens, blood and cerebrospinal. The use of multiplex panels is associated with quicker turnaround time, reduction of other unnecessary laboratory tests, faster diagnosis and targeted treatment.

Drivers

Rise in prevalence of infectious diseases
The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.

Rise in adoption of molecular diagnostic techniques
Molecular diagnostics also help address the need for tests that monitor the therapeutic efficacy of pharmaceuticals. In this way, diagnostic laboratories or other end-users provide the highest levels of reliability and the greatest speed

Recent Developments

In March 2021, BioFire Diagnostics (A Subsidiary of biomérieux SA) received the market authorization for BioFire respiratory panel 2.1, a diagnostic test for detecting and identifying multiple respiratory viral and bacterial infections nucleic acids in nasopharyngeal swabs. This has helped the company to commercialize its product
In March 2021, F. Hoffmann-La Roche Ltd entered into a definitive merger agreement for Roche to fully acquire GenMark Diagnostics. This has helped the company to increase its portfolio
Some of the major players operating in the global syndromic multiplex diagnostic market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Akonni Biosystems, Inc., Biocartis, QuantuMDx Group Ltd., Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH), Applied BioCode, Inc., Prominex Inc., Nanomix, Inc., Curetis (A subsidiary of OpGen, Inc.), and MiRXES Pte Ltd. among others.

To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-syndromic-multiplex-diagnostic-market

https://dbmrbuisness.blogspot.com/2023/05/clinical-trials-market-size-share.html

https://dbmrbuisness.blogspot.com/2023/05/internal-neurostimulation-devices.html

https://dbmrbuisness.blogspot.com/2023/05/digital-health-technologies-market-to.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.